Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis

NCT00255983 is registered in ClinicalTrials.gov with Replidyne as lead sponsor.

NCT NCT00255983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00255983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis
Lead sponsor
Replidyne
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2005
Completion date
June 30, 2008
Enrollment
491 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic bronchitis